New Delhi: The Andhra Pradesh State Council of Higher Education (APSCHE) has not released the final seat allotment results for B Pharmacy and Pharm D courses under AP EAMCET 2025. The decision comes in compliance with a directive issued by the Andhra Pradesh High Court. While allotments for engineering courses have been declared, the counselling process for pharmacy streams has been put on hold. According to the APSCHE official portal, "As per the Orders of the Honorable High Court of A.P dated:12.09.2025 in W.P. No. 24639/2025, seats for B.Pharmacy and Pharm-D courses have not been allotted. A separate notification will be issued shortly for conducting counselling for these courses." TheEconomic Timesreports that the Andhra Pradesh State Council of Higher Education (APSCHE) will issue a fresh notification for the counselling and seat allotment of BPharmacy and Pharm D programs once the ongoing legal proceedings are concluded. In the meantime, students aspiring for these courses have been advised to keep checking the official APSCHE website for regular updates. Also Read: Pharmacy Council sets 1:20 staff to students ratio, tightens faculty rules for B.Pharm programs
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!